💨 Abstract

India's Sun Pharmaceutical Industries has agreed to acquire U.S.-based Checkpoint Therapeutics, an immunotherapy and targeted oncology company, for $355 million. The deal will add UNLOXCYT, a treatment for advanced skin cancer, to Sun Pharma's global franchise. The transaction is expected to be completed in Q2 2025 and will be made through an upfront cash payment of $4.1

Courtesy: theprint.in

Summarized by Einstein Beta 🤖